Document Detail


Omega-3 polyunsatured fatty acids role in postmyocardial infarction therapy.
MedLine Citation:
PMID:  12855934     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Largely initiated by studies among Eskimos in the early 1970s, great attention has been given to possible effects of omega-3 polyunsatured fatty acids (PUFA) in cardiovascular diseases. A series of positive effects on pathogenetic mechanisms of cardiovascular disease has been discovered from laboratory studies in cell cultures, animal models and in humans. omega-3 PUFA can reduce platelets and leucocytes activities as well as plasma triglycerides. Moreover they can have antiarrhythmic properties. Nowadays patients who experienced myocardial infarction have decreased risk of total and cardiovascular mortality by treatment with omega-3 PUFA (1 g daily). This effect is present irrespective of high or low fish intake or simultaneous intake of other drugs for secondary prevention of coronary heart disease. Mainly on the basis of GISSI Prevention trial results, dietary supplementation with omega-3 PUFA is now recommended as a new component of secondary prevention after myocardial infarction in national and international guidelines.
Authors:
M Imazio; D Forno; C Quaglia; R Trinchero
Related Documents :
15242074 - Different clinical and coronary angiographic findings according to ratios of total chol...
7465464 - Dietary prevention at home and abroad.
19958964 - Effect of intensive statin therapy on clinical outcomes among patients undergoing percu...
10150224 - Surrogate end-points: the case of trials on coronary atherosclerotic plaque regression.
21798474 - Cardiac resynchronization therapy in patients with congenital heart disease.
2122984 - Reassessment of benefit-risk ratio and treatment algorithms for antiarrhythmic drug the...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Panminerva medica     Volume:  45     ISSN:  0031-0808     ISO Abbreviation:  Panminerva Med     Publication Date:  2003 Jun 
Date Detail:
Created Date:  2003-07-11     Completed Date:  2003-10-08     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  0421110     Medline TA:  Panminerva Med     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  99-107     Citation Subset:  IM    
Affiliation:
Cardiology Department, Maria Vittoria Hospital, Turin, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anti-Arrhythmia Agents / adverse effects,  metabolism,  therapeutic use*
Fatty Acids, Omega-3 / adverse effects,  metabolism,  therapeutic use*
Humans
Myocardial Infarction / drug therapy*,  prevention & control
Chemical
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/Fatty Acids, Omega-3

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hepatopulmonary syndrome. A review of the literature.
Next Document:  The impact of genes and pre- and postnatal environment on the metabolic syndrome. Evidence from twin...